Atorvia's research and development efforts are focused on maintaining and restoring organ function by preventing the regulated cell death pathways triggered by cell stress and injury.
Our lead therapeutic platform inhibits nucleophosmin-induced regulated cell death, a primary driver of organ failure. With a first-in-class therapeutic in pre-clinical development, Atorvia is first targeting the kidney with an initial indication for ischemic Acute Kidney Injury.
Preventing cell death.
Revolutionizing treatment for organ failure.